SMOX and myeloid sarcoma: To the best of our knowledge, this is the first report demonstrating the impact of SMOX inhibition on EAE-induced retinal neurodegeneration and inflammation, suggesting the potential benefits of SMOX inhibition to treat vision loss in MS patients.